Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | POR | P16435 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17078001 | 0.75 | PTPRC (0.45) | PTPRCNQO1PORCA1CA9 | |
| SCHEMBL19305291 | 0.75 | PTPRC (0.45) | PTPRCNQO1PORCA1CA9 | |
| SCHEMBL15287902 | 0.72 | PTPRC (0.42) | PTPRCNQO1PORMAOAMAOB | |
| SCHEMBL29385918 | 0.72 | PTPRC (0.42) | PTPRCNQO1PORCA1CA9 | |
| SCHEMBL30575214 | 0.70 | PTPRC (0.41) | PTPRCNQO1PORCA1CA9 | |
| SCHEMBL38665627 | 0.70 | PTPRC (0.41) | PTPRCNQO1PORCA1CA9 | |
| SCHEMBL29696352 | 0.70 | PTPRC (0.41) | PTPRCNQO1PORCA1CA9 | |
| SCHEMBL28782 | 0.67 | PTPRC (0.76) | PTPRCALOX15TDP1NQO1POR | |
| SCHEMBL3273316 | 0.67 | PTPRC (1.00) | PTPRCALOX15TDP1NQO1POR | |
| SCHEMBL9672807 | 0.67 | PTPRC (0.69) | PTPRCALOX15TDP1NQO1POR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111423583-B | Polyimide resin with furan structure and preparation method thereof | 浙江大学宁波理工学院 | 2022-06-07 | — | — | CN | claimed |
| CN-109021902-A | A kind of degradable epoxy resin adhesive of biology base and preparation method thereof | 扬州市文祺材料有限公司 | 2018-12-18 | — | — | CN | claimed |
| US-8653048-B2 | Prodrugs based on gemcitabine structure and synthetic methods and applications thereof | SANLUGEN PHARMATECH LTD. (CN) | 2014-02-18 | — | — | US | claimed |
| US-20120088908-A1 | Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof | SANLUGEN PHARMATECH LTD. (CN) | 2012-04-12 | — | — | US | claimed |
| EP-2423215-A1 | PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF | Sanlugen Pharmatech Ltd. (CN) | 2012-02-29 | — | — | EP | claimed |
| CN-102115485-A | Prodrug based on cytosine arabinoside structure, and synthesis method and application thereof | SANLUGEN PHARMATECH | 2011-07-06 | — | — | CN | claimed |
| CN-101525361-B | Prodrug based on gemcitabine structure as well as synthesizing method and application thereof | JINAN SHENGLUJIN PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2010-11-17 | — | — | CN | claimed |
| CN-101525361-A | Prodrug based on gemcitabine structure as well as synthesizing method and application thereof | SANLUGEN PHARMATECH DEV CO LTD | 2009-09-09 | — | — | CN | claimed |
| US-20090018264-A1 | RESIN COMPOSITION | CANON KABUSHIKI KAISHA (JP) | 2009-01-15 | — | — | US | claimed |
| CN-101343404-A | Resin composition | CANON KK (JP) | 2009-01-14 | — | — | CN | claimed |
| WO-2025124564-A1 | POLYESTER SYNTHESIS BASED ON ASPARTIC ACID MODIFICATION | 元素驱动(杭州)生物科技有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025108372-A1 | TEMPERATURE-RESISTANT POLYMER AND PREPARATION METHOD THEREFOR, AND USE OF CYCLIC IMIDE DIOL COMPOUND | 元素驱动(杭州)生物科技有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025108371-A1 | COPOLYMER WITH IMPROVED STRENGTH AND PREPARATION METHOD THEREFOR | 元素驱动(杭州)生物科技有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025021165-A1 | POLYMER COMPRISING ESTER-IMIDE STRUCTURAL UNIT, AND PREPARATION METHOD THEREFOR | 西湖大学 | 2025-01-30 | — | — | WO | disclosed |
| JP-2024055407-A | FIBER, FIBER BUNDLE AND TEXTILE PRODUCT | 三菱ケミカル株式会社 | 2024-04-18 | — | — | JP | disclosed |
| US-5770340-A | USING ELECTROGRAPHIC PRINTING PLATE HAVING ELECTROCONDUCTIVE SUPPORT WITH PHOTOCONDUCTIVE LAYER CONTAINING INORGANIC PHOTOCONDUCTOR, SPECIFIC SENSITIZING DYE AND BINDER, ALSO WITH BACKING HAVING LOW ELECTRICAL RESISTANCE | FUJI PHOTO FILM CO., LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| US-5677098-A | USING CYANINE DYE | FUJI PHOTO FILM CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| EP-0288083-B1 | Method of image formation which includes scanning exposure process | FUJI PHOTO FILM CO LTD (JP) | 1994-08-10 | — | — | EP | disclosed |
| US-4929527-A | DARK CHARGE RETAINING PROPERTIES | FUJI PHOTO FILM CO., LTD. (JP) | 1990-05-29 | — | — | US | disclosed |
| EP-0288083-A2 | Method of image formation which includes scanning exposure process | FUJI PHOTO FILM CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088908-A1 | Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof | TYMP, DCTD, GLS2 | PTPRC 4240/4885ALOX15 2359/4885TDP1 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.